31^st January 2007, London. ApaTech, a world leader in bone graft technology, announces the launch of Actifuse^TM E-Z-Prep, the latest entry in the Company’s product line.

Actifuse E-Z-Prep provides customers with Actifuse granules in an easy to use applicator that conveniently delivers Actifuse granules as a cohesive mass straight to the operative site. Using only the patient’s own blood or bone marrow aspirate, Actifuse E-Z-Prep provides surgeons with the handling benefits they associate with demineralised bone matrix putties whilst delivering the maximum packing density of useable graft.

Commenting on the launch of Actifuse E-Z-Prep, CEO Simon Cartmell said ease of use coupled with rapid bone formation means that surgeons need look no further than Actifuse E-Z-Prep for the majority of their bone grafting procedures. It avoids the costs of BMPs, the risks of DBMs and allograft and the additional operative challenges of harvesting autograft”

The unique silicate substituted calcium phosphate chemistry of Actifuse is a significant advance in synthetic bone graft technology and provides surgeons with a safe and effective alternative to both autograft and allograft. Actifuse enhances the formation of bone and improves the subsequent organisation and strength of the graft/host bone composite structure. Unlike traditional calcium phosphate based products, Actifuse is steadily and predictably remodelled by the host biology over time, ensuring that sufficient conductive scaffold remains for the duration of new bone growth and its subsequent maturation.

Distinct from allograft and demineralised bone matrix sourced from cadaveric bone, Actifuse is synthetic and as a result, free of pathogens. This means that there is no risk of infection due to human or animal infective agent transmission from the graft material, and being synthetic, there have been no reports of adverse immunological reactions.

Contact

Simon Cartmell, Chief Executive Officer +44 (0)20 8731 4640 or +44 (0)796 645 3133

About ApaTech

ApaTech Limited, based in London, England, is a world leader in bone graft technologies. Founded in 2001 and based on research and intellectual property from London and Cambridge Universities, ApaTech has introduced a novel silicate substituted calcium phosphate bone graft material, Actifuse^TM globally. The company believes that Actifuse is the first of a new class of synthetic bone graft material that combines osteoconductive and osteostimulatory activities.

To date the Company has raised £11.5m of equity from 3i plc and MTI and £2m of debt from Noble Ventures. ApaTech commercializes its products, Actifuse and ApaPore in 18 countries around the world and is achieving rapid sales growth.

To date the Company has raised £11.5m of equity from 3i plc and MTI and £2m of debt from Noble Ventures. ApaTech commercializes its products, Actifuse and ApaPore in 18 countries around the world and is achieving rapid sales growth.